glp-1 reviews oral Head-to-head trial shows Eli Lilly's orforglipron outperforms oral semaglutide Oral GLP-1 for Weight Loss:

Some of these issues could be alleviated with robust human-based research, followed by FDA approval if warranted

RBC Capital Markets described the subsequent decline in Lillys stock as an overreaction, noting that the overall safety profile remains favorable and emphasizing that one liver case does not make a signal. 1 Similarly, Evercore ISI analysts cautioned against overinterpretation, writing that we cannot look at this single liver case in a silo, particularly given that hepatic events have been reported across the GLP-1 class and may reflect confounding factors

Ueda P, Sderling J, Wintzell V, Svanstrm H, Pazzagli L, Eliasson B, et al

Updated July 1, 2023